A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01). (6th November 2014)

Record Type:: Journal Article
Title:: A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01). (6th November 2014)
Main Title:: A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)
Authors:: Clark, Joseph
Flaherty, Lawrence
Ernstoff, Marc
Koon, Henry
Milhem, Mohammed
Militello, Gerald
Agarwala, Sanjiv
Curti, Brendan
Cranmer, Lee
Lao, Christopher D
Logan, Theodore F
Lutzky, Jose
Rudrapatna, Venkatesh
Daniels, Gregory
Taback, Bret
Aung, Sandra
Lowder, James
Lawson, David
Abstract:
Is Part Of:: Journal for immunotherapy of cancer. Volume 2(2014)Supplement 3
Journal:: Journal for immunotherapy of cancer
Issue:: Volume 2(2014)Supplement 3
Issue Display:: Volume 2, Issue 3 (2014)
Year:: 2014
Volume:: 2
Issue:: 3
Issue Sort Value:: 2014-0002-0003-0000
Page Start:
Page End:
Publication Date:: 2014-11-06
Subjects:: Metastatic Melanoma -- Complete Response Rate -- Vemurafenib -- Tumor Debulking -- Aldesleukin
Cancer -- Immunotherapy -- Periodicals
Cancer -- Immunological aspects -- Periodicals
Tumors -- Immunological aspects -- Periodicals
Immunotherapy -- Periodicals
616.99406105
Journal URLs:: http://www.immunotherapyofcancer.org ↗
https://jitc.bmj.com/ ↗
http://link.springer.com/ ↗
DOI:: 10.1186/2051-1426-2-S3-P77 ↗
Languages:: English
ISSNs:: 2051-1426
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 19212.xml